NEW YORK (GenomeWeb News) – Murex Pharmaceuticals licensed from Ariadne Genomics its Pathway Studio software to help develop cancer therapeutics, Ariadne said yesterday.
Murex will use Pathway Studio to develop computer-based models to identify and validate cancer targets.

Financial details were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.